



September 18, 2020

Dear LAHO shareholders,

Lans Management is issuing this web-based press release to ensure all LAHO Share Holders that we stand by MSSV and the deal we have with them regarding the acquisition of GSCG. We were made aware today, along with the public, of the payment made by MSSV to GSCG. Several shareholders have raised the same questions with Lans IR team.

Therefore, Lans confirms again that MSSV is obligated to issue Preferred Shares to Lans as part of this transaction and everything remains the same with respect to LAHO common shareholders receiving preferred shares once the transaction is closed as per previous communications.

We all know that the acquisition of GSCG cannot be successfully completed until MSSV both updates their 10k and 10q filings as well as make the final payment to GSCG. We are excited for this transaction to complete, and although the timelines have needed some adjusting, nothing else has changed with respect to this transaction and managements expectation that this transaction will close.

It is Management's continued opinion that MSSV, through the acquisition of Global Stem Cells Group, has the potential to create significant impact in Regenerative Medicine and the BioTech Market as will create value for LAHO shareholders.

Please refer to this section of Lans website for any further communications that may be posted from time to time by Lans.

Thank you,

Investor Relations

Lans Holdings, Inc.